Your browser doesn't support javascript.
loading
Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
Yamanouchi, Masayuki; Skupien, Jan; Niewczas, Monika A; Smiles, Adam M; Doria, Alessandro; Stanton, Robert C; Galecki, Andrzej T; Duffin, Kevin L; Pullen, Nick; Breyer, Matthew D; Bonventre, Joseph V; Warram, James H; Krolewski, Andrzej S.
Afiliação
  • Yamanouchi M; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Skupien J; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Department of Metabolic Disease, Jagellonian University Medical College, Krakow, Poland. Electronic address: Jan.S
  • Niewczas MA; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Smiles AM; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Doria A; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Stanton RC; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Renal Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Galecki AT; Institute of Gerontology, University of Michigan Medical School, Ann Arbor, Michigan, USA; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Duffin KL; Lilly Research Laboratories, Eli Lilly & Company Inc. Corporate Center, Indianapolis, Indiana, USA.
  • Pullen N; Pfizer Inc., 610 Main Street, Cambridge, Massachusetts, 02139, USA.
  • Breyer MD; Lilly Research Laboratories, Eli Lilly & Company Inc. Corporate Center, Indianapolis, Indiana, USA.
  • Bonventre JV; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Renal Division, Brigham & Women Hospital, Boston, Massachusetts, USA.
  • Warram JH; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Krolewski AS; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: Andrzej.krolewski@joslin.harvard.edu.
Kidney Int ; 92(1): 258-266, 2017 07.
Article em En | MEDLINE | ID: mdl-28396115
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Fase III como Assunto / Seleção de Pacientes / Determinação de Ponto Final / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Taxa de Filtração Glomerular / Rim / Falência Renal Crônica Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Fase III como Assunto / Seleção de Pacientes / Determinação de Ponto Final / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Taxa de Filtração Glomerular / Rim / Falência Renal Crônica Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article